跳至主要内容
临床试验/NCT00260000
NCT00260000已完成2 期

Study of the Response of Tetrahydrobiopterin on S-Phenylalanine in Patients With PKU Housing the Y414C Mutation

The Kennedy Institute-National Eye Clinic2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2005年4月1日最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
15
试验地点
2
主要终点
Fasting S-phenylalanine at day 0, 1, 2, 5, 7 in each week of treatment with BH4.

研究概览

简要总结

The main purpose is to test whether treatment with BH4-tablets can replace the protein restrictive diet in patients with mild PKU caused by a certain frequent mutation.

详细描述

PKU, phenylketonuria, is a rare, inherited metabolic disorder that results in mental retardation if not a very strict low-protein diet is started within the first weeks of life.

The conversion of phenylalanine, phe, to tyrosine is defect, phe accumulates, leading to brain damage. There are different degrees of severity, reflecting the spectrum of mutant genes. BH4, tetrahydrobiopterin, is a co-enzym for the conversion of phe to tyrosine. It is known that BH4 can lower phe in some patients with milder forms of PKU.

The main purpose is to test whether treatment with oral BH4 can replace the protein restrictive diet in patients with mild PKU caused by the frequent mutation Y414C in the phenylalanine hydroxylase gene.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
8 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed mild PKU with 2 known mutations in the PAH gene, hereof at least one Y414C From the age of eight Informed consent -

排除标准

  • Less than 8 years of age Pregnancy or treated with the intensive diet of pregnancy

结局指标

主要结局

Fasting S-phenylalanine at day 0, 1, 2, 5, 7 in each week of treatment with BH4.

次要结局

未报告次要终点

研究者

发起方
The Kennedy Institute-National Eye Clinic
申办方类型
Other Gov

研究点 (2)

Loading locations...

相似试验